Foresite Capital

Foresite Capital is a San Francisco-based healthcare and life sciences crossover investment firm that invests across public and private markets in biotech, genomics, and precision medicine companies, applying a distinctive integrated investment approach combining venture capital, growth equity, and public market investing. The firm was founded by Jim Tananbaum and manages more than $6 billion in assets under management. Foresite's crossover model allows it to build relationships with companies at early private stages, continue supporting them through IPO and beyond. The firm applies deep genomics, computational biology, and clinical data expertise across drug discovery, diagnostics, precision oncology, and digital health. Portfolio companies include 10x Genomics, the single-cell genomics instrument company that completed a Nasdaq IPO in 2019; Absci, the AI-powered drug design company that completed a Nasdaq IPO in 2021; Akeso, the biopharmaceutical company; and Arrowhead Pharmaceuticals, the RNA interference therapeutics company listed on Nasdaq. Beyond its original investments, the portfolio includes additional genomics, biotech, and precision medicine companies.